Searched for
LATANOPROST
Glenmark launches generic ophthalmic solution in US marketGlenmark Pharmaceuticals' subsidiary has introduced Latanoprost ophthalmic solution, a generic medication for glaucoma, in the US market. T...- Want to grow hair again after experiencing baldness? Tech millionaire offers solution to menTech millionaire Bryan Johnson claimed to have reversed male pattern baldness and restored natural hair color within a year. Using nutritio...
- Essential medicines list: Govt adds 34 new drugs, drops 26; all you need to knowSeveral anti-cancer drugs, antibiotics and vaccines will now become more affordable as they are among 34 new additions to the National List...
- SPARC advances over 6% on getting USFDA's CRL for XelprosOn BSE, 1.14 lakh shares were traded on the counter in the first half an hour, compared with an average daily volume of 42,000 shares in th...
- USFDA nod for eyecare drug BromSite gives boost to Sun PharmaThe product will be commercialized through New Jersey-based Sun Ophthalmics, a division that Sun formed recently to route its specialty bra...
- USFDA denies approval for SPARC's anti-glaucoma eyedropSun Pharma Advanced Research Company (SPARC) today said the US health regulator has not approved its new drug application for anti-glaucoma...
- SPARC licenses Xelpros to Sun Pharma for US marketSun Pharma Advanced Research Company (SPARC) has licensed out Xelpros, a preservative-free eye drop, to a subsidiary of Sun Pharma for the ...
- SPARC rallies over 14% on receiving CRL from USFDA for Latanoprost NDASun Pharma Advanced Research Company Ltd (SPARC) rallied as much as 14.2 per cent in intraday trade on Monday.
- No USFDA approval for SPARC's anti-Glaucoma eyedropWhile the FDA did not seek any additional information for supporting clinical data, it sought additional information on certain labeling of...
- Sun Pharma Advanced Research Company to file new drug application for opthalmic solution in Q2 FY'14Sun Pharma Advanced Research Company (SPARC) today said it plans to file in the second quarter of the next financial year a new drug applic...
Load More
